Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivot
read at Endpoints ↗Positive readoutPositive
Cue Biopharma announced that its candidate for chronic spontaneous urticaria successfully completed a Phase 2 trial in China.
The trial marks the company's first clinical data since it shifted its focus from oncology to immunology.
The positive readout could position the drug as a potential competitor to existing treatments such as Xolair, though further development steps remain.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial”
read at Endpoints ↗87 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that